Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)
| Status: | Not yet recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 55 - 80 |
| Updated: | 3/14/2019 |
| Start Date: | April 1, 2019 |
| End Date: | February 1, 2023 |
| Contact: | Elyse R Park, Ph.D. |
| Email: | epark@mgh.harvard.edu |
| Phone: | (617) 724-6836 |
Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening
This randomized controlled trial seeks to evaluate the effectiveness of alternative
strategies to integrate smoking cessation interventions into the delivery of low-dose CT
(LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be
randomly assigned to receive these interventions: (1) smoking cessation counseling support by
telephone or videoconferencing (short duration vs. long duration); (2) nicotine patch
treatment (NRT) (short vs.long duration); (3) counselor-facilitated referral (vs. no
referral) to an online resource to connect smokers to a community-based social service
resources.
strategies to integrate smoking cessation interventions into the delivery of low-dose CT
(LDCT) lung cancer screening. Using a factorial design, current smokers who enroll will be
randomly assigned to receive these interventions: (1) smoking cessation counseling support by
telephone or videoconferencing (short duration vs. long duration); (2) nicotine patch
treatment (NRT) (short vs.long duration); (3) counselor-facilitated referral (vs. no
referral) to an online resource to connect smokers to a community-based social service
resources.
Evidence-based tobacco dependence treatment consists of behavioral counseling and
pharmacotherapy. Nicotine patch is an FDA-approved cessation aid. The optimal duration of
counseling and pharmacotherapy for patients undergoing low-dose CT (LDCT) lung screening is
not clear. In addition, helping smokers to address other social and psychological barriers
might help them succeed in quitting smoking. This randomized controlled trial will test, in a
factorial design, two options for delivering each of 3 interventions to help current smokers
stop smoking in the context of having routine CT lung cancer screening. Patients will receive
4 or 8 weeks of behavioral counseling (with their choice of video conferencing or regular
telephone calls), 2 or 8 weeks of nicotine patch, and will receive referral (vs. no referral)
to an online resource to connect smokers to community-based social service resources. Outcome
measures for smoking cessation will be assessed by a survey administered by phone at 3,and 6
months. Patients who self-report 7-day abstinence at 3- and 6- months follow-up will be asked
to provide a saliva sample to assay for cotinine.
pharmacotherapy. Nicotine patch is an FDA-approved cessation aid. The optimal duration of
counseling and pharmacotherapy for patients undergoing low-dose CT (LDCT) lung screening is
not clear. In addition, helping smokers to address other social and psychological barriers
might help them succeed in quitting smoking. This randomized controlled trial will test, in a
factorial design, two options for delivering each of 3 interventions to help current smokers
stop smoking in the context of having routine CT lung cancer screening. Patients will receive
4 or 8 weeks of behavioral counseling (with their choice of video conferencing or regular
telephone calls), 2 or 8 weeks of nicotine patch, and will receive referral (vs. no referral)
to an online resource to connect smokers to community-based social service resources. Outcome
measures for smoking cessation will be assessed by a survey administered by phone at 3,and 6
months. Patients who self-report 7-day abstinence at 3- and 6- months follow-up will be asked
to provide a saliva sample to assay for cotinine.
Inclusion Criteria:
- Scheduled to undergo LDCT-LCS at a participating Partners Health Care System LCS site
- Speak English or Spanish.
- Current smokers: smoked a cigarette, even a puff, in the last 30 days.
- Medicare coverage requirement (age 55-80 years, 30+ pack/years).
Exclusion Criteria:
- Undergoing lung CT as part of a diagnostic or abnormal follow-up evaluation.
- Unable to give informed consent due to psychiatric or cognitive impairment as
determined in consultation with study PI or treating clinician.
- No access to a telephone or cannot communicate by telephone.
We found this trial at
2
sites
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials